NASS are delighted to hear that NICE has recommended secukinumab (Cosentyx®) as an option for treating active AS in adults whose disease has responded inadequately to conventional therapy (non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors).
This recommendation has been published by NICE in what is called a Final Appraisal Determination (FAD). This means that there is still the possibility that an organisation could appeal against the decision. Any appeal must be received by 18 August 2016. However, we hope it will move quickly to become guidance. We will keep you updated.
The Scottish Medicines Consortium (SMC) has also completed its assessment of secukinumab and we are also delighted to report that it has been accepted for use within NHS Scotland. It can now be used in the treatment of active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy.
NASS Chief Executive Debbie Cook said:
“NASS is delighted that NICE and the SMC have given a positive decision on secukinumab (Cosentyx) for ankylosing spondylitis (AS). At the moment treatment options are very limited for people living with AS and this will offer a new option. We hope that now people affected by AS will be able to discuss the suitability of both secukinumab and the range of anti TNF therapies with their rheumatologist and decide together which would be the best option for them.”
Secukinumab is NOT an anti-TNF. It is a human monoclonal antibody that selectively neutralises circulating IL 17A. Research shows that IL 17A plays an important role in driving the body’s immune response in psoriasis and spondyloarthritis conditions, including psoriatic arthritis and AS.